Compass Therapeutics (CMPX) Net Income towards Common Stockholders: 2023-2025
Historic Net Income towards Common Stockholders for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to -$15.8 million.
- Compass Therapeutics' Net Income towards Common Stockholders fell 29.23% to -$15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$70.1 million, marking a year-over-year decrease of 41.55%. This contributed to the annual value of -$56.6 million for FY2024, which is 33.25% down from last year.
- According to the latest figures from Q3 2025, Compass Therapeutics' Net Income towards Common Stockholders is -$15.8 million, which was up 24.92% from -$21.1 million recorded in Q2 2025.
- Over the past 5 years, Compass Therapeutics' Net Income towards Common Stockholders peaked at -$7.8 million during Q1 2023, and registered a low of -$21.1 million during Q2 2025.
- Over the past 3 years, Compass Therapeutics' median Net Income towards Common Stockholders value was -$13.1 million (recorded in 2024), while the average stood at -$13.5 million.
- Data for Compass Therapeutics' Net Income towards Common Stockholders shows a maximum YoY slumped of 61.10% (in 2025) over the last 5 years.
- Compass Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$13.4 million in 2023, then dropped by 23.55% to -$16.6 million in 2024, then decreased by 29.23% to -$15.8 million in 2025.
- Its Net Income towards Common Stockholders stands at -$15.8 million for Q3 2025, versus -$21.1 million for Q2 2025 and -$16.6 million for Q1 2025.